DDInter1314 DDInter1652
Norgestimate was first described in the literature in 1977. It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects. It is commonly formulated with [ethinylestradiol] as a combined oral contraceptive that can also be used to treat moderate acne vulgaris.[L11845,L11848] Norgestimate was granted FDA approval on 29 December 1989.
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Norgestimate {u} (Compound) resembles {v} (Compound) Progesterone
Norgestimate {u} (Compound) binds {v} (Gene) PGR
Norgestimate {u} (Compound) upregulates {v} (Gene) DDIT4
Norgestimate {u} (Compound) is included by {v} (Pharmacologic Class) Progesterone Congeners
Norgestimate {u} (Compound) downregulates {v} (Gene) DPH2
Norgestimate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rosuvastatin
Norgestimate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etanercept
Norgestimate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Norgestimate {u} may lead to a major life threatening interaction when taken with {v} Griseofulvin
Norgestimate {u} may lead to a major life threatening interaction when taken with {v} Dabrafenib
Norgestimate (Compound) resembles Progesterone (Compound)
Norgestimate (Compound) binds PGR (Gene)
Norgestimate (Compound) upregulates DDIT4 (Gene)
Norgestimate (Compound) is included by Progesterone Congeners (Pharmacologic Class)
Norgestimate (Compound) downregulates DPH2 (Gene)
Norgestimate may cause a minor interaction that can limit clinical effects when taken with Rosuvastatin
Norgestimate may cause a moderate interaction that could exacerbate diseases when taken with Etanercept
Norgestimate may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Norgestimate may lead to a major life threatening interaction when taken with Griseofulvin
Norgestimate may lead to a major life threatening interaction when taken with Dabrafenib